Trial · NCT02011750
Pilot Trial of Valproate as Adjunctive Treatment for Toxoplasma Gondii Infection in Early Course Schizophrenia
NCT02011750, Phase 4, Completed, University of Pittsburgh
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Pilot Trial of Valproate as Adjunctive Treatment for Toxoplasma Gondii Infection in Early Course Schizophrenia. Trials, record NCT02011750. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02011750
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Pilot Trial of Valproate as Adjunctive Treatment for Toxoplasma Gondii Infection in Early Course Schizophrenia
- NCT number
- NCT02011750
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 109 participants, actual
- Lead sponsor
- University of Pittsburgh
- Conditions
- Toxoplasmosis, Schizophrenia
- Interventions
- Sodium Valproate treatment, Placebo
- First posted
- 2013-12-13
- Last updated
- 2018-02-14
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Clinical Severity | Clinical severity will be assessed during week 20 of the study. | Clinical Severity will be measured by the Positive and Negative Syndrome Scale (PANSS),a 7 point rating scale for 30 psychopathological items based on interviews or reports. |
| Primary | Cognitive Domains assessed via the Arabic version of the Penn CNB | Cognitive domains wil be measured in week 16 of the study | Cognitive domains will be assessed using the Arabic version of the Penn Computerized Neuropsychological Battery (CNB), which includes cognitive measures that distinguish SZ cases and relatives from controls. Accuracy and response time are recorded. |
| Primary | Social Function assessed via the Quality of Life Scale | Social functioing will be assessed during week during week 16. | Overall Social function will be measured by the Quality of Life Scale, which measures interpersonal, social and occupational functioning. |
| Primary | Cognitive domains assessed via Trails Making Test | Cognitive domains will be assessed in week 16 of the study | Cognitive domains will be assessed using the Trails Making Test, a neuropsychological test of attention and task switching. |
| Primary | Social Function -assessed via the GAF scale | Social functioning will be assessed during week 16 | Social functioning will be assessed using the Global Assessment of Functioning (GAF), a global measure of function and symptom severity. |
| Primary | Social Functioning assessed via the Short Form | Social functioning will be assessed during week 16 | Social functioning will be assessed via the Short Form, a multi-item scale that consists of 8 scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. |
| Secondary | Side effects | Side effects will be measured during week 20 of the study. | Participants will be monitored for adverse reactions to study medication through week 20. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests1
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as |
|---|---|
| Task Switching Test | Primary outcome |
Source ConductCognition
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02011750
GET https://conductscience.org/api/trials/v1/NCT02011750/registered